Open Beta
MetriLume

US marketsBMY

SEC-sourced researchBeta

BMY

BRISTOL MYERS SQUIBB CO

Company comparison ↗

Data passport

CIK
0000014272
Exchange
NYSE
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Nov 6, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 45,006,000,000.0000 USD; December 2024: 48,300,000,000.0000 USD; December 2025: 48,194,000,000.0000 USD48.3B USD0 USD0December 2023December 2024December 2025
BMY · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202345,006,000,000.0000Feb 11, 2026
December 202448,300,000,000.0000Feb 11, 2026
December 202548,194,000,000.0000Feb 11, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202548,194,000,000.00007,054,000,000.000014,156,000,000.000090,038,000,000.000071,533,000,000.0000Feb 11, 2026
December 202448,300,000,000.0000-8,948,000,000.000015,190,000,000.000092,603,000,000.000076,215,000,000.0000Feb 11, 2026
December 202345,006,000,000.00008,025,000,000.000013,860,000,000.0000——Feb 11, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

70/100
Profitability79
Growth50
Balance sheet21
Cash generation100
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$48.19BJan 1, 2025 – Dec 31, 2025Feb 11, 202610-K
Previous period revenueRevenues$48.3BJan 1, 2024 – Dec 31, 2024Feb 11, 202610-K
Net incomeNetIncomeLoss$7.05BJan 1, 2025 – Dec 31, 2025Feb 11, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$14.16BJan 1, 2025 – Dec 31, 2025Feb 11, 202610-K
Total assetsAssets$90.04BDec 31, 2025Feb 11, 202610-K
Total liabilitiesLiabilities$71.53BDec 31, 2025Feb 11, 202610-K

New filings

Explore methodology ↗